CTC landscape during HCC immunotherapy.

• DOI: 10.1200/jco.2025.43.16_suppl.4112
• Publication Date: 2025-05-28T14:27:31Z
• Authors: Marcos Santiago F...; Lauren Jung; Zhoubo Guo; Chetan Nambiar; Afnan Shaik; Namrata Anand; Joseph Wang Franses

4112 Background: The treatment of hepatocellular carcinoma (HCC), the third leading cause global cancer death, has significantly improved with advent immune checkpoint inhibitor regimens. Circulating tumor cells (CTCs) contain precursors metastasis and can be serially sampled while patients receive therapy. Quantification CTC dynamics during HCC therapy may yield early insight into systemic anticancer response profile. Methods: We used a commercially available microfluidic purification methodology followed by quantification CTCs expressing cell surface markers (EPCAM, ASGR1, GPC3) PD-L1 from receiving therapies, prior to cycle 1 3 also captured correlated clinical data, including conventional liver function (Child-Pugh score) radiographic for correlation changes in number. Results: In this pilot study,we collected total 29 specimens 14 participants, 10 whom provided serial samples. quantities detected was (median:10, range: 1-516); (median:1, 0-139) were high,(median: 8, 1-312) medium, (median: 3, 0-190) low. There no clear statistical difference enumeration data on treatment, although numbers subsets numerically declined many participants. Conclusions: statistically significant relationship between quantity subsequent response. Future studies will involve enrollment expanded comparisons circulating DNA dynamics, transcriptional profiling further explore these phenomena.